COMPASS Pathways (NASDAQ:CMPS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $120.00 price objective on the stock.

Several other research firms also recently commented on CMPS. Royal Bank of Canada began coverage on COMPASS Pathways in a report on Tuesday, July 23rd. They issued an outperform rating and a $23.00 price objective for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of COMPASS Pathways in a report on Friday, June 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average target price of $43.00.

COMPASS Pathways Stock Up 2.3 %

NASDAQ:CMPS opened at $7.04 on Wednesday. COMPASS Pathways has a 1-year low of $5.01 and a 1-year high of $12.75. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.23 and a quick ratio of 15.23. The firm’s 50-day moving average price is $6.89 and its 200-day moving average price is $8.58. The company has a market capitalization of $481.40 million, a PE ratio of -2.97 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). On average, equities analysts predict that COMPASS Pathways will post -2.24 EPS for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. bought a new stake in shares of COMPASS Pathways in the second quarter worth about $664,000. Blue Trust Inc. bought a new stake in COMPASS Pathways in the second quarter worth $81,000. Virtu Financial LLC bought a new stake in shares of COMPASS Pathways in the 1st quarter worth about $201,000. Tidal Investments LLC boosted its position in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock valued at $159,000 after buying an additional 5,795 shares during the period. Finally, Kennedy Capital Management LLC purchased a new position in COMPASS Pathways during the 1st quarter valued at $139,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.